Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Neurology

Can Thyroid Antibody Levels Predict SREAT Relapses?

At a Glance

Thyroid antibody levels do not reliably predict a SREAT relapse. New or returning changes in thinking, behavior, speech, movement, or seizures compared with your usual baseline are more useful warning signs, but a clinician must evaluate other causes.

It is natural to want a simple blood test that can warn you if a relapse is coming, but tracking your thyroid antibody levels is not an effective way to predict a SREAT (Hashimoto’s encephalopathy) relapse. Research shows that levels of anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies do not reliably correlate with how active the disease is or how severe your symptoms are [1][2].

While elevated thyroid antibodies may support a SREAT diagnosis in the right clinical context, they are common in people without brain inflammation and do not by themselves prove or disprove active disease [2][3]. In fact, studies have shown that your antibody levels can rise without triggering a clinical relapse, or they can drop even when you are experiencing severe symptoms [4][5]. Because of this disconnect, doctors do not rely on antibody numbers to determine if your condition is flaring up or to guide your treatment decisions [3][6].

There is currently no single validated blood test or routine surveillance schedule that reliably predicts a SREAT relapse [6].

How to Monitor Your Condition

Since blood tests cannot predict a flare-up, monitoring relies on close observation of your symptoms and working with your neurologist to establish your “normal” baseline. Because you may not notice gradual changes in your own thinking or behavior, involving a trusted family member or caregiver in monitoring is highly recommended.

Recognizing Potential Symptoms

The most useful indicator of a possible relapse is a change in your neurological or psychiatric function, especially if it resembles your initial episode [7]. You and your loved ones should watch for:

  • Confusion or altered awareness [8]
  • Memory impairment or difficulty paying attention [8][7]
  • Changes in behavior, mood, or psychiatric symptoms [8]
  • Speech difficulties or trouble communicating [8]
  • Gait disturbances (trouble walking) or loss of coordination [8]
  • Seizures or myoclonus (sudden, brief muscle jerks) [8][9]

Important Note on Symptoms: New or returning symptoms do not automatically prove a SREAT relapse. These changes can also be caused by ordinary infections, sleep deprivation, changes in your thyroid hormone levels, side effects from medication, or other neurological conditions. Any change from your baseline warrants a medical evaluation to rule out these other causes.

When to Seek Emergency Care

Do not wait for a routine appointment or an antibody test if you experience sudden, severe changes. Seek emergency medical help immediately if you or your loved one experiences:

  • A first-time seizure, a seizure lasting more than a few minutes, or repeated seizures without recovery
  • An inability to wake up or stay awake
  • Rapidly worsening confusion or severe agitation
  • Sudden, new weakness on one side of the body, or sudden loss of speech or vision
  • Any behavior that makes you or someone else unsafe

Medication Tapering

Relapses or changing symptoms can sometimes occur when corticosteroids or other immunotherapies are being reduced [7]. However, you should never start, stop, or change your medication doses without your prescriber’s explicit instruction. Abruptly stopping steroids can cause dangerous withdrawal and adrenal problems. Work with your doctor to create a specific contact and escalation plan before beginning any dose reductions.

Objective Medical Testing

If your symptoms change, your doctor will likely perform a broader medical work-up. Rather than relying on antibody tests, your clinician will select tests based on your specific symptoms to evaluate your brain and rule out other causes:

  • Electroencephalogram (EEG): An EEG measures the electrical activity of your brain. It is mainly used if seizures or altered awareness are suspected [8]. It can help identify subclinical seizures (seizures happening in the brain without obvious physical symptoms) [10]. However, abnormal EEG findings are not specific to SREAT, and a normal EEG does not completely rule out a relapse.
  • Cognitive and Neuropsychological Testing: Formal assessments can document your memory, attention, and executive function (planning, organizing, and managing tasks) [7][11]. While this testing cannot confirm that SREAT alone caused the decline, it provides a valuable comparison against your baseline over time.
  • Magnetic Resonance Imaging (MRI): MRI is not a validated measure of SREAT activity and is often completely normal even during a severe flare-up [12][13]. However, it remains an important tool for ruling out structural causes, strokes, or other types of brain inflammation.
  • Other Lab Work: Your doctor may check your TSH and free T4 to ensure your standard thyroid function is stable, and they may order metabolic, infection, or cerebrospinal fluid (CSF) testing to exclude other mimics of a SREAT relapse.

By tracking your symptoms against your established baseline and having an action plan in place, you and your care team can respond quickly and appropriately to any changes in your health.

Common questions in this guide

Can thyroid antibody levels tell me whether a SREAT relapse is coming?
No. Anti-TPO and anti-thyroglobulin antibody levels do not reliably track SREAT activity or symptom severity. They may rise without a relapse and may fall while symptoms are severe, so clinicians do not use the numbers alone to predict flares or guide treatment.
What is the best way to notice a possible SREAT relapse?
Watch for new or returning neurological or psychiatric changes compared with your usual baseline, such as confusion, memory or attention problems, behavior or mood changes, speech trouble, walking difficulty, seizures, or myoclonus. A trusted family member or caregiver may notice gradual changes that are hard for you to detect.
Is there a routine blood test or monitoring schedule that predicts SREAT relapses?
There is no single validated blood test or routine surveillance schedule that reliably predicts a SREAT relapse. If symptoms change, your clinician will choose tests based on your symptoms and check for other causes such as infection, sleep loss, thyroid hormone changes, medication effects, or another neurological condition.
What tests might I need if SREAT symptoms return?
Depending on your symptoms, your clinician may use an EEG, cognitive or neuropsychological testing, MRI, thyroid tests, metabolic and infection tests, or cerebrospinal fluid testing. These tests help assess brain function and rule out other causes; none alone proves or completely rules out a SREAT relapse.
What should I do if symptoms return while my steroid dose is being reduced?
Contact your prescribing clinician according to the action plan you made before tapering. Do not start, stop, or change corticosteroids or other immunotherapy on your own, because abrupt steroid withdrawal can be dangerous.
When should someone with a possible SREAT relapse seek emergency help?
Get emergency help for a first seizure, a seizure lasting more than a few minutes, repeated seizures without recovery, inability to wake or stay awake, rapidly worsening confusion or severe agitation, sudden one-sided weakness, sudden loss of speech or vision, or unsafe behavior. These symptoms need urgent assessment rather than waiting for an antibody test or routine appointment.

Get notified when new evidence is published on Steroid-responsive encephalopathy associated with autoimmune thyroiditis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    A Case of Steroid-Responsive Encephalopathy.

    Kondramashin A, Filatov A, Grossman JT, Swerdloff M

    Cureus 2021; (13(8)):e17063 doi:10.7759/cureus.17063.

    PMID: 34522541
  2. 2

    Hashimoto's Encephalopathy: Case Series and Literature Review.

    Chaudhuri J, Mukherjee A, Chakravarty A

    Current neurology and neuroscience reports 2023; (23(4)):167-175 doi:10.1007/s11910-023-01255-5.

    PMID: 36853554
  3. 3

    Hashimoto's Encephalopathy: Clinical Features, Therapeutic Strategies, and Rehabilitation Approaches.

    Manocchio N, Magro VM, Massaro L, et al.

    Biomedicines 2025; (13(3)) doi:10.3390/biomedicines13030726.

    PMID: 40149702
  4. 4

    Beyond Pediatric Sleep Disorders: A Case of Hypersomnia Revealing Hashimoto's Encephalopathy.

    Delplace M, Andrei A, Van Hecke A

    Cureus 2025; (17(8)):e89543 doi:10.7759/cureus.89543.

    PMID: 40777071
  5. 5

    Hashimoto encephalopathy in pediatric patients: Homogeneity in clinical presentation and heterogeneity in antibody titers.

    Lee J, Yu HJ, Lee J

    Brain & development 2018; (40(1)):42-48 doi:10.1016/j.braindev.2017.07.008.

    PMID: 28784301
  6. 6

    Patients with a relapsing course of steroid-responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ T-cell activation.

    Pfeuffer S, Ruck T, Rolfes L, et al.

    European journal of neurology 2021; (28(4)):1284-1291 doi:10.1111/ene.14657.

    PMID: 33230897
  7. 7

    [A suspected case of Hashimoto encephalopathy with frequent relapses despite multiple courses of immunotherapy].

    Harada S, Inatomi Y, Nakajima M, Yonehara T

    Rinsho shinkeigaku = Clinical neurology 2020; (60(3)):200-205 doi:10.5692/clinicalneurol.cn-001361.

    PMID: 32101843
  8. 8

    Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature.

    Laurent C, Capron J, Quillerou B, et al.

    Autoimmunity reviews 2016; (15(12)):1129-1133 doi:10.1016/j.autrev.2016.09.008.

    PMID: 27639840
  9. 9

    Hashimoto encephalopathy: A study of the clinical profile, radiological and electrophysiological correlation in a Tertiary Care Center in South India.

    Sharma PM, Javali M, Mahale R, et al.

    Journal of neurosciences in rural practice 2015; (6(3)):309-14 doi:10.4103/0976-3147.158753.

    PMID: 26167010
  10. 10

    Hashimoto's Encephalopathy Presenting with Smoldering Limbic Encephalitis.

    Nagano M, Kobayashi K, Yamada-Otani M, et al.

    Internal medicine (Tokyo, Japan) 2019; (58(8)):1167-1172 doi:10.2169/internalmedicine.1289-18.

    PMID: 30982805
  11. 11

    Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) presenting as major depression.

    Endres D, Perlov E, Stich O, Tebartz van Elst L

    BMC psychiatry 2016; (16()):184 doi:10.1186/s12888-016-0897-3.

    PMID: 27268005
  12. 12

    MRI and steroid-responsive encephalopathy associated with autoimmune thyroiditis: first report of conus medullaris involvement and literature review of the known neuroimaging profiles.

    Cipriano L, Miele G, Ugga L, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(5)):1773-1776 doi:10.1007/s10072-023-06642-x.

    PMID: 36809420
  13. 13

    Serial brain MRI changes related to autoimmune pathophysiology in Hashimoto encephalopathy with anti-NAE antibodies: A case-series study.

    Matsunaga A, Ikawa M, Kawamura Y, et al.

    Journal of the neurological sciences 2019; (406()):116453 doi:10.1016/j.jns.2019.116453.

    PMID: 31525528

This page is for informational purposes only and does not constitute medical advice. Discuss new or returning symptoms, emergency concerns, or medication changes with your neurologist and prescribing clinician.